Sophia Genetics SA is a Swiss-founded data-driven medicine software company[2][3] with headquarters in Rolle, Switzerland and Boston, Massachusetts, as well as offices in France.[4][5] It provides genomic and radiomic, and multimodal analysis for hospitals, laboratories, and biopharma institutions.[6][7]
Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL). It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions.[8]
In 2014, the company introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine),[9][10] which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples.[11] The platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research.[11]
In August 2020, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus.[15] Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio.[1]
In March 2025, the company announced it had hit the milestone of 2 million genomic profiles analysed with its Sophia DDM platform.[18]
Technology
In 2014, Sophia Genetics introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine).[19] The data analytics platform allows clinicians to improve genomic diagnostics by applying AI to enhance next-generation sequencing methods.[20] The DDM platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research.[20] The company initially designed the platform to help hospitals process and store large genomic data sets, but after research showed the more important issue with the technology was data accuracy, the platform's focus shifted.[20]
In 2018, Sophia Genetics acquired Nénuphar, a technology that uses patient data and algorithms to predict tumor growth.[21][22]
Partnerships
In 2016, Sophia Genetics entered into a comarketing agreement with Illumina allowing the two companies to promote adoption of next- generation DNA sequencing.[23]
In 2021, the company partnered with MGI, a subsidiary of BGI Group, to enable their users to access the SOPHiA DDM Platform for data analysis and interpretation.[26] In March 2021, Sophia Genetics announced a long-term collaboration agreement with Hitachi.[27] That same year, Sophia Genetics also worked with GE HealthCare to build an analytics platform that matches patients' treatment regimens for their specific genomic signature, cancer type, and lifelong health record.[28]
In 2022, the firm committed to a collaboration with Memorial Sloan Kettering Cancer Center to advance predictive tumor analysis and, more broadly, clinical decision support.[1]
In March 2023, the German biotechnology company Qiagen and Sophia Genetics paired their company's technology together for somatic variant detection.[29] In october of the same year, the company entered a partnership with the pharmaceutical company AstraZeneca and Memorial Sloan Kettering Cancer Center to offer to more hospitals and patients around the world access to MSK's blood and tumor sequencing tests via Sophia's data-driven medicine platform.[30]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
